Abstract：[Abstract] Objective To observe the effect of Tirofiban in the percutaneous coronary intervention (PCI) for elderly patients with hish-risk non-ST-elevation acute coronary syndrome (NSTE-ACS). Methods Three hundred and twenty cases of elderly patients with hish-risk NSTE-ACS receiving PCI in Daping Hospital and the Research Institute of Surgery of the Third Military Medical University from February 2012 to February 2015 were selected and divided into two groups including 162 cases of control group (conventional treatment) and 158 cases of observation group (conventional treatment + Tirofiban). The TIMI myocardial perfusion grading before and after PCI of the two groups was compared, the clinical efficacy of the two groups was analyzed, the platelet aggregation levels and platelet count of the two groups were measured, the incidence of major adverse cardiovascular event (MACE) was recorded after a follow-up period of 30 d, and the incidence of bleeding complications was observed. Results The TIMI myocardial perfusion grades after PCI were significantly better than the control group (P ＜ 0.05); the total effective rate of observation group was 93.7%, which was significantly higher than that of control group (87.0%) (P ＜ 0.05); the platelet aggregation rate after PCI in observation group (0.29±0.09) was also significantly lower than that of control group (0.40±0.10) (P ＜ 0.05); follow-up for 30 d after PCI, the incidence of MACE in observation group (8.9%) was significantly lower than that of control group (14.2%) (P ＜ 0.05); while the incidence of bleeding complications between the two groups had no significant differences (P ＞ 0.05). Conclusion For elderly patients with hish-risk NSTE-ACS, Tirofiban can significantly improve TIMI myocardial perfusion levels, reduce platelet aggregation, improve clinical efficacy and short-term clinical prognosis, without increasing the risk of bleeding, which is worthy of clinical application.
[参考文献]
[1] Rinfret S，Potter BJ. Weekend warriors：can early invasive management of stable non-ST-elevation acute coronary syndromes save health care dollars? [J]. Can J Cardiol，2015，31（3）：250-252.
[2] Eyübo■lu M. What is the real predictive value of red cell distribution width for the mortality in non-ST elevation acute coronary syndrome? [J]. Anatol J Cardiol，2015，15（9）：770-771.
[3] 陈刚，黄婷，杨锴.经皮冠状动脉介入术治疗对女性冠心病患者长期生活质量和预后的影响[J].中国医药导报，2013，10（32）：80-82.
[4] 任琳，王文广，王倩，等.低剂量替罗非班在老年急性ST段抬高心肌梗死急诊冠脉介入治疗中的应用[J].实用老年医学，2014，28（1）：37-40.
[5] Chang ST，Chung CM，Chu CM，et al. Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury [J]. Int Heart J，2015，56（3）：335-340.
[6] Patel PD，Arora RR. Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction [J]. Am J Ther，2010，17（1）：e24-e40.
[7] Liu Y，Liu H，Hao Z，et al. Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention（PCI）[J]. Int J Clin Exp Med，2015， 8（7）：11360-11369.
[8] Widimsky P，Motovska Z，Bolognese L，et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel [J]. Heart，2015，101（15）：1219-1224.
[9] Bethke A，Halvorsen S，B?覬hmer E，et al. Myocardial perfusion grade predicts final infarct size and left ventricular function in patients with ST-elevation myocardial infarction treated with a pharmaco-invasive strategy（thrombolysis and early angioplasty）[J]. Euro Intervention，2015，11（5）：518-524.
[10] Barros V，Pereira M，Araújo C，et al. Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal：the EURHOBOP study [J]. Rev Port Cardiol，2015，34（7-8）：449-456.
[11] Angeli F，Cavallini C，Verdecchia P，et al. A risk score for predicting 1-year mortality in patients ≥75 years of age presenting with non-ST-elevation acute coronary syndrome [J]. Am J Cardiol，2015，116（2）：208-213.
[12] Keles N，Kalcik M，Caliskan M，et al. The effects of urgent percutaneous coronary intervention on right ventricular systolic functions in non-ST-elevation acute coronary syndromes [J]. Interv Med Appl Sci，2015，7（2）：69-77.
[13] 尹萍，殷兆芳，许左隽，等.75岁以上ACS患者冠脉病变特点及PCI术后1年随访结果[J].心血管康复医学杂志，2014，23（5）：530-533.
[14] Besic KM，Strozzi M，Margetic E，et al. Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome [J]. J Cardiol，2015，65（3）：203-207.
[15] 徐风燕，迟新栋，帕尔哈提，等.替罗非班与低相对分子质量肝素钙在预防支架内血栓形成的对比研究[J].血栓与止血学，2013，19（4）：156-157，181.
[16] Puri A，Bansal A，Narain VS，et al. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI [J]. Indian Heart J，2013，65（2）：152-157.
[17] 王立中，俞晓薇，赵冬婧，等.替罗非班联用前列地尔对急诊经皮冠脉介入治疗术后心肌梗死患者心肌再灌注和心功能短期预后的影响[J].中国医药导报，2013， 10（17）：77-79，82.
[18] 张春萍，汪莉，赵鑫，等.老年血液流变学参数变化与动脉粥样硬化危险因素的相关分析[J].老年医学与保健，2011，17（1）：35-37，40.
[19] 黄涛，李奇俊.血浆脑钠肽水平与急性冠状动脉综合征患者心血管事件的相关性研究[J].检验医学与临床，2014， 11（9）：1210-1212.
[20] 张晶，王艳飞，贾新未，等.非ST段抬高型急性冠脉综合征患者药物治疗前后血浆B型尿钠肽水平变化及其与冠脉病变程度的关系分析[J].中国医药导报，2014， 11（8）：147-149，154.
[21] 张爱军，蔡茵萍，谢亚平，等.前列地尔注射液对非ST段抬高型急性冠脉综合征患者PTX3水平的影响[J].中国医药导报，2014，11（5）：60-63.
[22] Dehghani MR，Rezaei Y，Taghipour-Sani L. White blood cell count to mean platelet volume ratio as a novel non-invasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome [J]. Cardiol J，2015，22（4）：437-445.
京公网安备 11010502046598号